回复 16楼Shengbing的帖子 Once an application by Gilead Sciences is made, the Japanese government is set to fast-track its approval. This streamlining of the process -- which involves postponing reports on domestic clinical tests to a later date -- is available on condition that the drug has been approved in another country. 有条件指的是如果走fast track
The New England Journal of Medicine recently published a study showing the drug's effectiveness in nearly 70 percent of 53 coronavirus patients with severe symptoms, while it caused serious side-effects, such as deterioration of kidney function, in a quarter of them. 怎么是肾脏有严重副作用？上次不是说肝脏吗？
About a quarter of Covid-19 patients put on ventilators in New York's largest health system died, study finds https://www.cnn.com/2020/04/22/health/coronavirus-ventilator-patients-die/index.html the patients receivedremdesivir for up to 10 days. Over 18 days, 68% showed improvement, with 17 of the 30 patients on ventilators able to be taken off the devices. Almost half of patients were discharged, while 13% died. Mortality was highest in patients receiving ventilation, with 18% dying.
That being said, about 25% of patients receiving it have severe side effects, including multiple-organ dysfunction syndrome, septic shock, acute kidney injury and low blood pressure. Another 23% demonstrated evidence of liver damage on lab tests.
25%的严重副作用，把呼吸机上25%的死亡率降到18%，Gilead自己都没你这么牛呢。真是神药，美国怎么还死了快6万人？大统领敢推氯喹，甚至消毒剂紫外线，为什么不推瑞德西韦？ About a quarter of Covid-19 patients put on ventilators in New York's largest health system died, study finds https://www.cnn.com/2020/04/22/health/coronavirus-ventilator-patients-die/index.html the patients receivedremdesivir for up to 10 days. Over 18 days, 68% showed improvement, with 17 of the 30 patients on ventilators able to be taken off the devices. Almost half of patients were discharged, while 13% died. Mortality was highest in patients receiving ventilation, with 18% dying. That being said, about 25% of patients receiving it have severe side effects, including multiple-organ dysfunction syndrome, septic shock, acute kidney injury and low blood pressure. Another 23% demonstrated evidence of liver damage on lab tests. ca563 发表于 4/28/2020 8:38:00 AM
你贴的那几段不全面，明显只贴了你想让大家看到的一面 我也来贴一点正面的😆 有没有用，等gilead 最后的结果吧 “We cannot draw definitive conclusions from these data, but the observations from this group of hospitalized patients who received remdesivir are hopeful,” said lead author Jonathan Grein, director of hospital epidemiology at Cedars-Sinai Medical Center in Los Angeles
你贴的那几段不全面，明显只贴了你想让大家看到的一面 我也来贴一点正面的😆 有没有用，等gilead 最后的结果吧 “We cannot draw definitive conclusions from these data, but the observations from this group of hospitalized patients who received remdesivir are hopeful,” said lead author Jonathan Grein, director of hospital epidemiology at Cedars-Sinai Medical Center in Los Angeles victoriabaobei 发表于 2020-04-28 09:02
“We cannot draw definitive conclusions from these data, but the observations from this group of hospitalized patients who received remdesivir are hopeful,” said lead author Jonathan Grein, director of hospital epidemiology at Cedars-Sinai Medical Center in Los Angeles victoriabaobei 发表于 4/28/2020 9:02:23 AM
我只是copy了数据部分，评论部分你为什么只贴了一半？下面这半怎么不一起转过来？
Researchers doubt this recent study data is anything more than suggestive, if that. “The data from this paper are almost uninterpretable,” Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, told Bloomberg. “There is some evidence suggesting efficacy, but we simply do not know what would have happened to these patients had they not been given the drug.” Which is why more organized clinical trials with controls are necessary.
对啊，你贴的这段说明data is uninterpretable， 那么你之前说这药没用的结论也一样不可信
我只是copy了数据部分，评论部分你为什么只贴了一半？下面这半怎么不一起转过来？ Researchers doubt this recent study data is anything more than suggestive, if that. “The data from this paper are almost uninterpretable,” Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, told Bloomberg . “There is some evidence suggesting efficacy, but we simply do not know what would have happened to these patients had they not been given the drug.” Which is why more organized clinical trials with controls are necessary. ca563 发表于 4/28/2020 9:15:00 AM
About a quarter of Covid-19 patients put on ventilators in New York's largest health system died, study finds https://www.cnn.com/2020/04/22/health/coronavirus-ventilator-patients-die/index.html the patients receivedremdesivir for up to 10 days. Over 18 days, 68% showed improvement, with 17 of the 30 patients on ventilators able to be taken off the devices. Almost half of patients were discharged, while 13% died. Mortality was highest in patients receiving ventilation, with 18% dying.
That being said, about 25% of patients receiving it have severe side effects, including multiple-organ dysfunction syndrome, septic shock, acute kidney injury and low blood pressure. Another 23% demonstrated evidence of liver damage on lab tests.
澎湃新闻
13小时前 · 澎湃新闻官方账号
日本媒体报道称，日本政府将很快对新冠肺炎候选治疗药物瑞德西韦进行“特例批准”，瑞德西韦预计将成为日本首款可以使用的新冠肺炎治疗药物。 据日本共同社4月27日报道，首相安倍晋三当天透露，对瑞德西韦“很快可以进行药事批准”。共同社援引日本政府相关人士的话称，瑞德西韦适用于简化审查手续的“特例批准”，但条件是在海外使用获批。 共同社指出，日本政府预计瑞德西韦近期将会在欧美获得使用批准，若有日本企业申请引进，政府将推进相关手续。 在日本研究机构所参与的一项临床研究中，使用瑞德西韦的53名新冠肺炎重症患者中有近七成症状有所缓解，但另有四分之一的患者出现了肾功能损坏等较为严重的副作用。 据澎湃新闻（www.thepaper.cn）4月17日报道，美国芝加哥大学进行的一项临床试验中，在使用瑞德西韦治疗新冠肺炎重症患者后，患者发烧和呼吸道症状迅速消失，几乎所有病人都在不到一周内出院。 但《美国医学会杂志》近日发布的一篇研究表明，迄今为止还没有证据表明存在治疗新冠肺炎的特效药。瑞德西韦目前也尚未在全球任何国家获得批准，对于治疗新型冠状病毒肺炎的安全性或有效性尚不明确。 瑞德西韦在中国的一项试验近日也被宣告“终止”，临床实验网站ClinicalTrials.gov上原因显示为：“中国的新冠肺炎疫情已经得到良好控制，当前没有符合条件的患者入组。” 5.6万阅读
日本疫情 更新时间 2020/04/27 18:58
Another source: https://english.kyodonews.net/news/2020/04/96de780ad3e1-japan-to-approve-remdesivir-for-coronavirus-patients-in-may.html
🔥 最新回帖
这么敏感？呵呵
我股票已经抛了，落袋为安，不需要选择什么
你是在说自己吧，根本没选择的人更可怜
🛋️ 沙发板凳
上面有介绍日本的实验结果
看起来是有条件的。
对啊，很多药在国内上市也是一样的，
先在EU或者美国获批，然后用那个authorization申请国内的approval。
美国国立卫生研究院（NIH）和日本国家国际医学研究中心（NIMR）一直在进行remdesivir对新型冠状病毒的疗效的
联合试验。
跟厉害国没有关系。日本新闻里也没有提到厉害国。
预计很快就会在德国和美国获得批准，在日本申请后，政府将办理特别审批手续。 预计将在听取卫生、劳动和福利部相关理事会的意见后予以批准。
就是说德国和美国快要批准了。
对，inconclusive 就是inconclusive， 非要提交成negative
让人不得不往政治挂帅上想
都能跑到twitter上公开造谣美军投毒的政府，你能指望啥
之前看新闻说美国的试验很快要出来，最早在五月初，难道安倍是得到了这方面的内部消息？
不清楚，日本读买新闻是这么说的。
患者不够？你这是开玩笑还是认真的？
武汉都清零了，你说呢？
我发现你智商真有问题，要不就是脑子被洗坏了，你说你天天翻墙过来恶心人干嘛呢？
不知道谁的智商低，自己去了解下，中国做这个实验分轻症和重症，重症患者不足，实验被迫停止
你们就等着报应吧
你们最好还是赶快祈祷这个药真没效果吧，就像你们一直宣传的那样。
如果这个药事实证明有效，全世界都会记住你们抢注专利、私自仿制药品、破坏临床实验、泼脏水抹黑别人的嘴脸。
时间不多了，美国对这个药作最终评价可能就在这两个星期。
25%的严重副作用，把呼吸机上25%的死亡率降到18%，Gilead自己都没你这么牛呢。真是神药，美国怎么还死了快6万人？大统领敢推氯喹，甚至消毒剂紫外线，为什么不推瑞德西韦？
About a quarter of Covid-19 patients put on ventilators in New York's largest health system died, study finds https://www.cnn.com/2020/04/22/health/coronavirus-ventilator-patients-die/index.html the patients receivedremdesivir for up to 10 days. Over 18 days, 68% showed improvement, with 17 of the 30 patients on ventilators able to be taken off the devices. Almost half of patients were discharged, while 13% died. Mortality was highest in patients receiving ventilation, with 18% dying.
That being said, about 25% of patients receiving it have severe side effects, including multiple-organ dysfunction syndrome, septic shock, acute kidney injury and low blood pressure. Another 23% demonstrated evidence of liver damage on lab tests.
你该去医院查查脑子了，典型的迫害妄想症
楼上有几位练功练到走火入魔了
不用的时候重症死亡率也就是不到20%，用了以后能过挺过副作用的人死亡率变成18%，有多少因为副作用死了不知道。不过新英格兰医学杂志明确说了，有23%的人出现休克和多器官衰竭，25%的人肝坏死。这样的药批准了也没人敢用，股托们放出来拉高股价割韭菜而已。
你们因为你们的傲慢和偏见正在遭受报应，如果还继续甩锅，撒谎，泼脏水，报应不知道什么时候是个头，积点口德吧，好好监督你们的政府赶快用心对抗疫情吧，别整天把放大镜对着别人
CNN刚报过，纽约上呼吸机的死亡率是25%，那位的9成死亡率不知道是哪来的。但日本这条新闻引用的小trial是在波士顿做的，显然跟纽约的数据更有可比性。
这话对你说也很合适。天天掏放大镜看别人的是厉害国吧，等着吧，报应会有的
这些人自己窝在重灾区中心的纽约地下室里，还专注大洋彼岸中国是不是多了几个阳性。这份心怀天下的情怀，干点别的早就成功了。
我给的link是报道纽约上呼吸机后的死亡率是25%，是驳那位张口就来9成死亡率的。
下面的那两段是Boston那个小study的数据总结，原文link在这里 https://www.biospace.com/article/data-from-gilead-s-compassionate-use-of-remdesivir-for-covid-19-looks-promising/
23%多器官衰竭、中毒性休克，25%肝坏死，居然能说成这个药是”hopeful”，为了拉高股价连起码的良心都不要了。
我只是copy了数据部分，评论部分你为什么只贴了一半？下面这半怎么不一起转过来？
Researchers doubt this recent study data is anything more than suggestive, if that. “The data from this paper are almost uninterpretable,” Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, told Bloomberg. “There is some evidence suggesting efficacy, but we simply do not know what would have happened to these patients had they not been given the drug.” Which is why more organized clinical trials with controls are necessary.
他们天天把国内的负面消息往华人转也就罢了，但明目张胆的造谣实在太下作了。
它一傻缺，屏蔽了事，不值得浪费时间
跟这种新注册的带任务id有什么好说的，屏蔽完了
很正常，这药一开始是给ebola设计的，那种立马毙命的烈性病完全不用考虑副作用，能救一命是一命，新冠不一样，这么严重的副作用不是大家能接受的。不过现在所有药厂都在加班加点绞尽脑汁看自己的asset能不能用来治新冠，美国又有大把的病人可以做trial （sadly），我觉得还是有希望把药找出来的
外宣带节奏是发帖的目的，否则中共干嘛给这些造谣贴伍毛七毛的。这种事太下贱，脑子正常的还真干不了
这个study只有53个病人，还没有对照组。结果也是重症死亡率从普通的25%变成18%。还不知道是不是瑞德西韦的功效，而且副作用严重，你们愿意用就用呗。你们浪费这么多功夫发贴，还不如去大统领Twitter下面多喊喊，说不定他看见了，继消毒剂以后，也帮忙推一推这个“神药”呢。
https://www.businessinsider.com/coronavirus-ventilators-some-doctors-try-reduce-use-new-york-death-rate-2020-4https://www.physiciansweekly.com/mortality-rate-of-covid-19-patients-on-ventilators/
https://www.bloomberg.com/news/articles/2020-04-22/almost-9-in-10-covid-19-patients-on-ventilators-died-in-study
上面三个链接里面，上了呼吸机的都是九死一生。
人家新闻上说得是上了呼吸机的25%迅速死了。 还有70%在ICU一直待的和刚刚进ICU的，结果还说不清楚。但凡是结果已经清楚的，上了呼吸机的那是88%的死了。那么真正的死亡率恐怕在25%到88%之间。 就算我们乐观一点，那70%死活还说不清的里面，只有20%最后死了，那呼吸机上的最终死亡率也是40%。
对比一下目前人民的希望，插管的用药18天后， 56%不用插管，18%死了。 这还不好么？
我说你们五毛断章取义有意思么？